<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995045</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00053514</org_study_id>
    <nct_id>NCT01995045</nct_id>
  </id_info>
  <brief_title>Postoperative Pain Control Following Vitreoretinal Surgery</brief_title>
  <official_title>The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if patients receiving a steroid (triamcinolone
      acetonide) combined with local anesthesia and antibiotic following retina surgery have better
      postoperative pain control those receiving local anesthesia and antibiotic alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients undergoing vitreoretinal surgery at the Emory Eye Center and Emory
      University Hospital receive a injection of local anesthesia behind the eye (retrobulbar) at
      the start of surgery to minimize discomfort felt during the surgery. At the end of surgery
      all patients receive a periocular antibiotic and steroid injection. Some patients also
      receive a retrobulbar injection of local anesthesia (bupivicaine) at the conclusion of
      surgery in order to decrease postoperative pain and discomfort.

      It has been our observation that when the local anesthesia is combined with a steroid
      (triamcinolone acetonide) in a retrobulbar injection at the conclusion of surgery, patients
      tend to be pain free for longer intervals then when local anesthesia is used alone. The
      objective of this study is to evaluate if patients receiving triamcinolone acetonide combined
      with local anesthesia and antibiotic compared to those receiving local anesthesia and
      antibiotic alone do better with postoperative pain control.

      All eligible patients undergoing vitreoretinal surgery at the Emory Eye Center and Emory
      University Hospital will be offered enrollment. About 60 patients will be invited to
      participate in this study. Patients will undergo standard of care surgery. At the conclusion
      of surgery, patients will receive a retrobulbar antibiotic and anesthetic as standard of
      care. Half of the patients will receive this mixture plus steroid and the other half will
      receive this mixture plus saline. On postoperative day 1, patients will be given a
      questionnaire to assess pain. Pain levels in the two groups will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Score</measure>
    <time_frame>Post-Operative Day 1 (Up to 24 hours)</time_frame>
    <description>The mean pain score assessed by the Visual Analog Pain Scale ranging from 0-10; 10 being the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Acetaminophen Intake</measure>
    <time_frame>Post Surgery (Up to 24 hours)</time_frame>
    <description>The mean acetaminophen use post surgery in milligrams(mg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hydrocodone Intake</measure>
    <time_frame>Post Surgery (Up to 24 hours)</time_frame>
    <description>The mean hydrocodone use post surgery in milligrams(mg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Oxycodone Intake</measure>
    <time_frame>Post Surgery (Up to 24 hours)</time_frame>
    <description>The mean oxycodone use post surgery in milligrams(mg).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Retinal Detachment</condition>
  <condition>Proliferative Vitreoretinopathy</condition>
  <condition>Retinoschisis</condition>
  <arm_group>
    <arm_group_label>Bupivicaine &amp; Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrobulbar anesthesia with Bupivicaine Hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Retrobulbar anesthesia</description>
    <arm_group_label>Bupivicaine &amp; Triamcinolone</arm_group_label>
    <other_name>Kenalog</other_name>
    <other_name>Triamcinolone Acetonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine Hydrochloride</intervention_name>
    <description>Retrobulbar anesthesia</description>
    <arm_group_label>Bupivicaine &amp; Triamcinolone</arm_group_label>
    <arm_group_label>Bupivicaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing vitreoretinal surgery at the Emory Eye Center Ambulatory Surgery
             Center and Emory University Hospital by retina attending faculty surgeons

        Exclusion Criteria:

          -  Unable to verbalize level of pain control

          -  Pediatric patients (&lt;18 years old)

          -  Glaucoma, ocular hypertension, or glaucoma suspects

          -  Allergy to local anesthetic

          -  Pre-existing chronic pain requiring narcotic pain medication

          -  Drug addiction

          -  Impaired periorbital sensation (history of herpes simplex, zoster, corneal graft)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy W Olsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gioia L, Prandi E, Codnotti M, Casati A,et al Peribulbar anesthesia with either 0.75% ropivacaine or a 2% lidocaine and 0.5% bupivacaine mixture for vitreoretinal surgery: a double-blinded study. Anesth Analg(89: 739-742, 1999. Shende D, Sadhasivam S, Madan R. Effects of peribulbar bupivacaine as an adjunct to general anaesthesia on peri-operative outcome following retinal detachment surgery. Anaesthesia(55): 970-975, 2000. Morel J, Pascal J, Charier D, et al. Preoperative peribulbar block in patients undergoing retinal detachment surgery under general anesthesia: a randomized double-blind study. Anesth Analg (102): 1082-1087, 2006. Ghali AM, Btarny AM. The effect on outcome of peribulbar anesthesia in conjunction with general anesthesia for vitreoretinal surgery. Anaesthesia (65): 249-253, 2010. Chavan SB, Cummings EJ.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <results_first_submitted>December 27, 2016</results_first_submitted>
  <results_first_submitted_qc>December 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Timothy W. Olsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Retina</keyword>
  <keyword>Vitreoretinal</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Retinoschisis</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from Emory University Hospital between October 1, 2012 and June 17, 2016 who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both.</recruitment_details>
      <pre_assignment_details>Of the 58 participants recruited for the study, data for 57 participants were analyzed. Data for one participant was not available for analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivicaine &amp; Triamcinolone</title>
          <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
        </group>
        <group group_id="P2">
          <title>Salt Solution, Bupivacaine, and Cefazolin</title>
          <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivicaine &amp; Triamcinolone</title>
          <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
        </group>
        <group group_id="B2">
          <title>Salt Solution, Bupivacaine, and Cefazolin</title>
          <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Score</title>
        <description>The mean pain score assessed by the Visual Analog Pain Scale ranging from 0-10; 10 being the worst possible pain.</description>
        <time_frame>Post-Operative Day 1 (Up to 24 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine &amp; Triamcinolone</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
          </group>
          <group group_id="O2">
            <title>Salt Solution, Bupivacaine, and Cefazolin</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Score</title>
          <description>The mean pain score assessed by the Visual Analog Pain Scale ranging from 0-10; 10 being the worst possible pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.8"/>
                    <measurement group_id="O2" value="3.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Acetaminophen Intake</title>
        <description>The mean acetaminophen use post surgery in milligrams(mg).</description>
        <time_frame>Post Surgery (Up to 24 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine &amp; Triamcinolone</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
          </group>
          <group group_id="O2">
            <title>Salt Solution, Bupivacaine, and Cefazolin</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Acetaminophen Intake</title>
          <description>The mean acetaminophen use post surgery in milligrams(mg).</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" spread="998"/>
                    <measurement group_id="O2" value="962" spread="839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hydrocodone Intake</title>
        <description>The mean hydrocodone use post surgery in milligrams(mg).</description>
        <time_frame>Post Surgery (Up to 24 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine &amp; Triamcinolone</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
          </group>
          <group group_id="O2">
            <title>Salt Solution, Bupivacaine, and Cefazolin</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hydrocodone Intake</title>
          <description>The mean hydrocodone use post surgery in milligrams(mg).</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" spread="2.9"/>
                    <measurement group_id="O2" value="2.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Oxycodone Intake</title>
        <description>The mean oxycodone use post surgery in milligrams(mg).</description>
        <time_frame>Post Surgery (Up to 24 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivicaine &amp; Triamcinolone</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/1 mL), 1 mL cefazolin (100mg/mL), and 1 mL triamcinolone (40mg/mL) at the end of surgery.</description>
          </group>
          <group group_id="O2">
            <title>Salt Solution, Bupivacaine, and Cefazolin</title>
            <description>Participants who were scheduled to have scleral buckle surgery, 20-gauge vitrectomy, or both were randomized to receive an injection of a 3-mL mixture of 1 mL 0.75% bupivacaine (7.5 mg/mL), 1 mL of balanced salt solution (BSS), and 1 mL cefazolin (100mg/mL) at the end of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Oxycodone Intake</title>
          <description>The mean oxycodone use post surgery in milligrams(mg).</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="6.8"/>
                    <measurement group_id="O2" value="9.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivicaine &amp; Triamcinolone</title>
          <description>Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
Triamcinolone: Retrobulbar anesthesia
Bupivicaine Hydrochloride: Retrobulbar anesthesia</description>
        </group>
        <group group_id="E2">
          <title>Bupivicaine</title>
          <description>Retrobulbar anesthesia with Bupivicaine Hydrochloride
Bupivicaine Hydrochloride: Retrobulbar anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timothy Olsen</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-4996</phone>
      <email>tolsen@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

